Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. This is the phase when you make key decisions that will have long-term scientific and business impact, frequently under extreme time and cost pressure.
Our protein design and optimization services help identify and mitigate manufacturing and development risks, reduce attrition and improve the quality and safety of therapeutic proteins.
In this early phase it is critical to have access to experts that understand your development journey. Your tailored conversation topics can include:
De-risking your lead
– Assessment and manufacturability screening
– Protein engineering
– Humanization
Preventing an unwanted immune response
– De-immunization
– Immunogenicity
Generating materials for your in vitro and preclinical studies
– Non-GMP protein expression and supply
– Guaranteed antibody supplyup to 2 g within 6 weeks
Compliance with regulatory guidance for IND
– In-silico and in-vitro immunogenicity/immunotoxicity assessment
Learn more here.
To schedule a meeting, send an E-mail to Mattias Nyström,
Senior Business Development Manager, Nordic countries
Mattias.Nystrom@lonza.com
